Lv21
140 积分 2024-06-28 加入
Molecular targets of tyrosine kinase inhibitors in thyroid cancer
3小时前
待确认
Genomic alterations in thyroid cancer: biological and clinical insights
3小时前
已完结
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials
24天前
已完结
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
1个月前
已完结
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis
2个月前
已完结
Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study
2个月前
已完结
An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma
2个月前
已完结
The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer
3个月前
已完结
Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma
3个月前
已完结
Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer
3个月前
已完结
皖公网安备34019202002308
